Directly Intercepting Autoimmune Signaling: Yarrow Launches Phase 2 Trial of YB-101
After completing its merger with VYNE and securing approximately $200 million in funding, Yarrow has begun testing an antibody that directly blocks TSHR; the first proof-of-concept data are expected in the second half of 2027.